|
Title
|
|
|
|
Impact of changing reimbursement criteria on the use of fluoroquinolones in Belgium
|
|
|
Author
|
|
|
|
|
|
|
Abstract
|
|
|
|
| Objectives: The criteria for the reimbursement of fluoroquinolones changed in Belgium on 1 May 2018. This study aims to quantify the difference in fluoroquinolone use after this change, and to assess the timing and persistence of this effect, both in terms of total reimbursed fluoroquinolone use and its relative proportion. Methods: Longitudinal reimbursement data on fluoroquinolone use in the Belgian community from January 2017 to November 2018 were analysed to identify a change in reimbursed fluoroquinolone use expressed in DDD per 1000 inhabitants per day (DID), using a set of non-linear mixed models including change-points. In addition, longitudinal data on the relative proportion of prescribed fluoroquinolones from January 2017 to December 2018 were analysed to identify a change in the relative proportion of prescribed fluoroquinolones using generalized estimation equations including change-points. Results: Fluoroquinolone use dropped significantly immediately after the change in reimbursement criteria, from 2.21 DID (95% CI: 2.03-2.38) to 0.52 DID (95% CI: 0.48-0.56) and from 9.14% (95% CI: 8.75%-9.56%) to 6.52% (95% CI: 6.04%-7.04%). The observed decrease in fluoroquinolone use persisted over time. Conclusions: While fluoroquinolone use was still above the target of 5% after the change in reimbursement criteria, its implementation helped to lower fluoroquinolone use in Belgium. |
|
|
|
Language
|
|
|
|
English
|
|
|
Source (journal)
|
|
|
|
The journal of antimicrobial chemotherapy. - London, 1975, currens
|
|
|
Publication
|
|
|
|
London
:
2021
|
|
|
ISSN
|
|
|
|
0305-7453
[print]
1460-2091
[online]
|
|
|
DOI
|
|
|
|
10.1093/JAC/DKAB255
|
|
|
Volume/pages
|
|
|
|
76
:10
(2021)
, p. 2725-2732
|
|
|
ISI
|
|
|
|
000701465700033
|
|
|
Pubmed ID
|
|
|
|
34374778
|
|
|
Full text (Publisher's DOI)
|
|
|
|
|
|
|
Full text (open access)
|
|
|
|
|
|